Dr. Nils Lonberg joined the venture capital firm Canaan Partners in 2019.
He was the senior vice president of Biologics Discovery and head of Oncology Discovery at Bristol-Myers Squibb. Previously, Dr. Lonberg led a group that developed transgenic mice which have helped scientists discover effective new medicines for humans, including five FDA-approved antibody products. In recognition of his accomplishments, he was elected to the National Academy of Engineering. In addition to being a member of CRI’s Scientific Advisory Council, Dr. Lonberg serves on the Cancer Immunotherapy Consortium (CIC) Steering Committee.
I’m very proud of [our] Immuno-Oncology discovery team - years of their groundbreaking work have led to what is now widely recognized as a revolutionary time in cancer research.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.